1887

Abstract

is an opportunistic protozoan pathogen that can cause blinding keratitis and a rare but fatal encephalitis involving the central nervous system with a very poor prognosis. This is due to limited availability of effective anti-acanthamoebic drugs. Here, we tested whether the use of liposomes can improve the potency of pentamidine isethionate, an anti-amoebic compound. The liposomes consisted of --phosphatidylcholine and cholesterol or ergosterol in a molar ratio of 1 : 5. Pentamidine isethionate was incorporated to achieve a final drug to lipid ratio of 1 : 5. At a drug concentration of 10 μg ml, the liposomal drug was >12 times more effective than the free drug at preventing binding to human cells and significantly more effective in reducing parasite-mediated human cell cytopathogenicity, compared with the drug alone. Both the free and liposomal drug blocked encystation.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.006494-0
2009-03-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/3/327.html?itemId=/content/journal/jmm/10.1099/jmm.0.006494-0&mimeType=html&fmt=ahah

References

  1. Alizadeh, H., Silvany, R. E., Meyer, D. R., Dougherty, J. M. & McCulley, J. P. ( 1997; ). In vitro amoebicidal activity of propamidine and pentamidine isethionate against Acanthamoeba species and toxicity to corneal tissues. Cornea 16, 94–100.
    [Google Scholar]
  2. Alsam, S., Kim, K. S., Stins, M., Rivas, A. O., Sissons, J. & Khan, N. A. ( 2003; ). Acanthamoeba interactions with human brain microvascular endothelial cells. Microb Pathog 35, 235–241.[CrossRef]
    [Google Scholar]
  3. Antimisiaris, S. G., Ioannou, P. V. & Loiseau, P. M. ( 2003; ). In vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in vivo distribution. J Pharm Pharmacol 55, 647–652.[CrossRef]
    [Google Scholar]
  4. Ficker, L., Seal, D., Warhurst, D. & Wright, P. ( 1990; ). Acanthamoeba keratitis – resistance to medical therapy. Eye 4, 835–838.[CrossRef]
    [Google Scholar]
  5. Khan, N. A. ( 2001; ). Pathogenicity, morphology, and differentiation of Acanthamoeba. Curr Microbiol 43, 391–395.[CrossRef]
    [Google Scholar]
  6. Khan, N. A. ( 2006; ). Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol Rev 30, 564–595.[CrossRef]
    [Google Scholar]
  7. Marciano-Cabral, F. & Cabral, G. ( 2003; ). Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 16, 273–307.[CrossRef]
    [Google Scholar]
  8. Ning, M. Y., Guo, Y. Z., Pan, H. Z., Yu, H. M. & Gu, Z. W. ( 2005; ). Preparation and evaluation of proliposomes containing clotrimazole. Chem Pharm Bull (Tokyo) 53, 620–624.[CrossRef]
    [Google Scholar]
  9. Paul, M., Durand, R., Fessi, H., Rivollet, D., Houin, R., Astier, A. & Deniau, M. ( 1997; ). Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob Agents Chemother 41, 1731–1734.
    [Google Scholar]
  10. Sissons, J., Kim, K. S., Stins, M., Jayasekera, S., Alsam, S. & Khan, N. A. ( 2005; ). Acanthamoeba castellanii induces host cell death via a phosphatidylinositol 3-kinase-dependent mechanism. Infect Immun 73, 2704–2708.[CrossRef]
    [Google Scholar]
  11. Stins, M. F., Gilles, F. & Kim, K. S. ( 1997; ). Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 76, 81–90.[CrossRef]
    [Google Scholar]
  12. Turner, N. A., Russell, A. D., Furr, J. R. & Lloyd, D. ( 2000; ). Emergence of resistance to biocides during differentiation of Acanthamoeba castellanii. J Antimicrob Chemother 46, 27–34.[CrossRef]
    [Google Scholar]
  13. Visvesvara, G. S., Moura, H. & Schuster, F. L. ( 2007; ). Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 50, 1–26.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.006494-0
Loading
/content/journal/jmm/10.1099/jmm.0.006494-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error